Her2-Positive Breast Cancer - China Drug Market Analysis to 2023

Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.

To Browse a Full Report with Toc: http://www.researchmoz.us/pharmapoint-her2-positive-breast-cancer-us-drug-forecast-and-market-analysis-to-2023-report.html

The high incidence of HER2-positive breast cancer in the US, almost equaling that of the entire 5EU, and the high treatment rates in the neoadjuvant and adjuvant settings using HER2-targeted therapies in all stages, have helped drive the sales of HER2-positive therapeutics in the US. HER2-targeting therapies are priced at a premium in the US, owing to the countrys private health insurance system, which can most easily afford to reimburse the latest expensive drugs.

Scope

An overview of HER2-Positive Breast Cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

Annualized the US HER2-Positive Breast Cancer market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.

Investigation of current and future market competition for HER2-Positive Breast Cancer.

Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.

Competitor assessment including device approval analysis and device sales forecasts.

Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.

Analysis of unmet needs within the...